CY1120213T1 - Antαγωνιστες φθοριωμενης ιντεγκρινης - Google Patents

Antαγωνιστες φθοριωμενης ιντεγκρινης

Info

Publication number
CY1120213T1
CY1120213T1 CY20171101252T CY171101252T CY1120213T1 CY 1120213 T1 CY1120213 T1 CY 1120213T1 CY 20171101252 T CY20171101252 T CY 20171101252T CY 171101252 T CY171101252 T CY 171101252T CY 1120213 T1 CY1120213 T1 CY 1120213T1
Authority
CY
Cyprus
Prior art keywords
macular edema
integrine
antagonists
compounds
determined
Prior art date
Application number
CY20171101252T
Other languages
English (en)
Inventor
Ben C. Askew
Richard W. Heidebrecht
Takeru Furuya
Mark E. Duggan
D. Scott Edwards
Original Assignee
Scifluor Life Sciences, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scifluor Life Sciences, Inc filed Critical Scifluor Life Sciences, Inc
Publication of CY1120213T1 publication Critical patent/CY1120213T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε φθοριωμένες ενώσεις του Χημικού Τύπου I και μεθόδους σύνθεσης αυτών των ενώσεων. Επίσης, η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις που περιέχουν τις φθοριωμένες ενώσεις της εφεύρεσης και μεθόδους θεραπείας της εκφύλισης της ωχράς κηλίδας, της διαβητικής αμφιβληστροειδοπάθειας (ΔΑ), του οιδήματος της ωχράς κηλίδας, του διαβητικού οιδήματος της ωχράς κηλίδας (ΔΟΩ) και του οιδήματος της ωχράς κηλίδας από απόφραξη φλέβας του αμφιβληστροειδούς (RVO), με χορήγηση αυτών των ενώσεων και των φαρμακευτικών συνθέσεων σε άτομα που την χρειάζονται.
CY20171101252T 2013-02-07 2017-11-29 Antαγωνιστες φθοριωμενης ιντεγκρινης CY1120213T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762087P 2013-02-07 2013-02-07
US201361900706P 2013-11-06 2013-11-06
PCT/US2014/015372 WO2014124302A1 (en) 2013-02-07 2014-02-07 Fluorinated integrin antagonists

Publications (1)

Publication Number Publication Date
CY1120213T1 true CY1120213T1 (el) 2018-12-12

Family

ID=51300167

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101252T CY1120213T1 (el) 2013-02-07 2017-11-29 Antαγωνιστες φθοριωμενης ιντεγκρινης

Country Status (24)

Country Link
US (6) US9518053B2 (el)
EP (3) EP3674301A1 (el)
JP (2) JP6494528B2 (el)
KR (1) KR102216091B1 (el)
CN (2) CN108690022B (el)
AU (1) AU2014214737B2 (el)
BR (2) BR112015019039B1 (el)
CA (1) CA2899321C (el)
CY (1) CY1120213T1 (el)
DK (1) DK2953948T3 (el)
ES (2) ES2763556T3 (el)
HK (2) HK1217696A1 (el)
HR (1) HRP20171873T1 (el)
HU (1) HUE035357T2 (el)
IL (2) IL240181A (el)
LT (1) LT2953948T (el)
ME (1) ME02938B (el)
PL (1) PL2953948T3 (el)
PT (1) PT2953948T (el)
RS (1) RS56711B1 (el)
RU (1) RU2698195C2 (el)
SI (1) SI2953948T1 (el)
WO (1) WO2014124302A1 (el)
ZA (1) ZA201505575B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2763556T3 (es) * 2013-02-07 2020-05-29 Scifluor Life Sciences Inc Antagonistas fluorados de integrina
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
PT3050878T (pt) 2013-09-24 2021-12-02 Fujifilm Corp Novo composto contendo azoto ou seu sal, ou seu complexo de metal
WO2015175954A1 (en) * 2014-05-16 2015-11-19 Scifluor Life Sciences, Inc. Alpha v integrin antagonist compositions
TWI736529B (zh) * 2015-02-19 2021-08-21 美商賽氟洛生命科學公司 氟化之四氫啶基壬酸衍生物及其用途
CN108040467A (zh) 2015-04-30 2018-05-15 赛弗卢尔生命科学公司 四氢萘啶基丙酸衍生物及其用途
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
MX2019000043A (es) * 2016-07-05 2019-07-04 Univ Rockefeller Antagonistas de integrina de tetrahidronaftiridinpentanamida.
KR102515507B1 (ko) * 2016-11-08 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 피롤 아미드
EP3538527B1 (en) * 2016-11-08 2021-10-13 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
WO2021231581A1 (en) 2020-05-12 2021-11-18 Scifluor Life Sciences, Inc. METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS
WO2023230042A1 (en) * 2022-05-23 2023-11-30 Ocuterra Therapeutics, Inc. Treating diabetic retinopathy using an integrin inhibitor
WO2024006248A1 (en) * 2022-06-27 2024-01-04 Ocuterra Therapeutics, Inc. Stable ophthalmic formulations of a fluorinated integrin antagonist
CN116239665A (zh) * 2023-03-10 2023-06-09 山东大学 Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1318254C (en) 1988-01-06 1993-05-25 Munehiro Tomikawa Inhibitory agent of hepatic fibrosis containing pantethine
DE69220050T2 (de) 1991-04-01 1998-01-22 Univ Duke Verfahren zur inhibierung der fibrose
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
JP3818322B2 (ja) 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US5736357A (en) 1994-10-27 1998-04-07 Arris Pharmaceutical Cathespin O protease
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
BR9813769A (pt) * 1997-12-17 2000-10-10 Merck & Co Inc Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste.
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AU736026B2 (en) * 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
EP1040111B1 (en) * 1997-12-17 2005-06-22 Merck & Co., Inc. Integrin receptor antagonists
CN1284955A (zh) * 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
US6117445A (en) 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
EP1140809B1 (en) * 1998-12-16 2005-08-31 Bayer HealthCare AG New biphenyl and biphenyl-analogous compounds as integrin antagonists
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
ES2288861T3 (es) * 1999-06-02 2008-02-01 MERCK & CO., INC. Antagonistas de los receptores de las integrinas alfa v.
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
US6455539B2 (en) * 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP4787447B2 (ja) 2000-01-20 2011-10-05 メルク・シャープ・エンド・ドーム・コーポレイション αｖインテグリン受容体拮抗薬
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
HUP0201284A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient
GB0011817D0 (en) 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
ATE353219T1 (de) 2000-07-26 2007-02-15 Merck & Co Inc Alpha v integrin-rezeptor-antagonisten
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2001292598B2 (en) 2000-09-14 2006-06-29 Merck & Co., Inc. Alpha V integrin receptor antagonists
AU2001295038A1 (en) * 2000-09-18 2002-03-26 Merck & Co., Inc. Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist
EP1444231A4 (en) 2001-11-06 2005-11-09 Merck & Co Inc AMINO SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST
US20040053968A1 (en) * 2001-12-28 2004-03-18 Hartman George D. Methods and compositions for treating peridontal disease
WO2004026233A2 (en) * 2002-09-20 2004-04-01 Merck & Co., Inc. Mannitol formulation for integrin receptor antagonist
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
CA2540730C (en) 2003-10-01 2012-08-21 Merck Patent Gmbh Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
WO2011060395A1 (en) 2009-11-16 2011-05-19 Schering Corporation Cyclic ureas useful as hiv inhibitors
EP2576540B1 (en) 2010-05-26 2019-09-04 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
AU2012253511A1 (en) 2011-05-09 2014-01-09 Allegro Pharmaceuticals, Inc. Integrin receptor antagonists and their methods of use
EP2726057A1 (en) 2011-06-28 2014-05-07 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing sorafenib
ES2763556T3 (es) * 2013-02-07 2020-05-29 Scifluor Life Sciences Inc Antagonistas fluorados de integrina
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
TWI736529B (zh) 2015-02-19 2021-08-21 美商賽氟洛生命科學公司 氟化之四氫啶基壬酸衍生物及其用途
CN108040467A (zh) 2015-04-30 2018-05-15 赛弗卢尔生命科学公司 四氢萘啶基丙酸衍生物及其用途
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds

Also Published As

Publication number Publication date
KR20150115812A (ko) 2015-10-14
RS56711B1 (sr) 2018-03-30
DK2953948T3 (en) 2017-12-18
RU2015137785A (ru) 2017-03-14
PL2953948T3 (pl) 2018-03-30
IL240181A0 (en) 2015-09-24
ES2763556T3 (es) 2020-05-29
EP2953948A4 (en) 2016-06-22
US9518053B2 (en) 2016-12-13
US20210163473A1 (en) 2021-06-03
EP2953948B1 (en) 2017-09-27
RU2698195C2 (ru) 2019-08-23
AU2014214737A1 (en) 2015-08-13
JP6494528B2 (ja) 2019-04-03
CA2899321C (en) 2021-03-09
HK1248677A1 (zh) 2018-10-19
US20170071939A1 (en) 2017-03-16
EP3674301A1 (en) 2020-07-01
ES2651162T3 (es) 2018-01-24
CN108690022B (zh) 2021-08-17
CN108690022A (zh) 2018-10-23
US20170291900A1 (en) 2017-10-12
US20160075698A1 (en) 2016-03-17
HK1217696A1 (zh) 2017-01-20
NZ710447A (en) 2020-10-30
US11685737B2 (en) 2023-06-27
ZA201505575B (en) 2022-03-30
LT2953948T (lt) 2018-01-10
JP2016507571A (ja) 2016-03-10
BR112015019039B1 (pt) 2022-03-03
JP2019108377A (ja) 2019-07-04
CA2899321A1 (en) 2014-08-14
US20190263810A1 (en) 2019-08-29
KR102216091B1 (ko) 2021-02-16
IL245471B (en) 2018-03-29
HUE035357T2 (en) 2018-05-02
CN105246889B (zh) 2018-07-31
EP3266782B1 (en) 2019-10-30
US10106537B2 (en) 2018-10-23
US20240140942A1 (en) 2024-05-02
AU2014214737B2 (en) 2017-07-27
BR122019026750B1 (pt) 2022-03-03
SI2953948T1 (en) 2018-02-28
HRP20171873T1 (hr) 2018-02-23
US9717729B2 (en) 2017-08-01
WO2014124302A1 (en) 2014-08-14
BR112015019039A2 (pt) 2017-07-18
ME02938B (me) 2018-04-20
IL240181A (en) 2016-06-30
IL245471A0 (en) 2016-06-30
EP2953948A1 (en) 2015-12-16
BR112015019039A8 (pt) 2019-11-12
EP3266782A1 (en) 2018-01-10
CN105246889A (zh) 2016-01-13
PT2953948T (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
CY1125436T1 (el) Αναστολεις dna-pk
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1121153T1 (el) Παραγωγα εξενδινης-4 ως διπλοι glp1/gιp- ή τριγωνικοι αγωνιστες glp1/gιp/γλυκαγονης
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CY1123996T1 (el) Υποκατεστημενα παραγωγα οξοπυριδινης
CY1119110T1 (el) Ρυθμιστες ρ2χ7
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201890159A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
CY1119047T1 (el) Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112017017888A2 (pt) derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
EA201600478A1 (ru) Новые индазолкарбоксамиды, способы их получения, содержащие их фармацевтические препараты и их применение для изготовления лекарственных средств
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CY1119615T1 (el) Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич